Registration Number
0225U001213,
(0123U100711)
, R & D reports
Title
To develop a method of antitumor therapy of primary malignant bone tumors, based on magnetochemical technology using nanocomplexes
popup.stage_title
Визначити ефективність протипухлинного впливу нанокомплексів у дослідах in vivo на тваринах з перещепленою саркомою з використанням апарату «Магнітерм».
Head
Orel Valerii E., Доктор біологічних наук
Registration Date
28-01-2025
Organization
National Cancer Institute
popup.description1
To improve the effectiveness of complex treatment of patients with bone sarcoma of high degree of malignancy.
popup.description2
Research object: Rat heart cells, animals with sarcoma-45 and Walker-256 carcinosarcoma, patients with sarcoma, liposomal and free forms of doxorubicin, radiofrequency electromagnetic radiation. Equipment: “Magniterm” shortwave inductothermy device (Radmir), electron paramagnetic resonance spectrometer PE1307 (ZEPS AN). Objective: to improve the effectiveness of comprehensive treatment for patients with high-grade malignant bone sarcomas. Research methods: laboratory, computer modeling, bioengineering, physico-chemical, and statistical methods. Electromagnetic radiation parameters were selected according to computer modeling using COMSOL Multiphysics 5.6 software for studying experimental animal tumors in vivo. Experiments showed that the combined effect of free or liposomal doxorubicin and electromagnetic radiation at moderate inductive hyperthermia on rat heart cells in vitro increased the number of living cells by 40 % and 26 % (p < 0.05) respectively, compared to the separate action of the drugs. Local exposure to non-ionizing electromagnetic radiation at moderate inductive hyperthermia in animals with sarcoma-45 initiated a 34 % (p < 0.05) reduction in tumor growth factor compared to the untreated animal group. The combined effect of free or liposomal doxorubicin and local electromagnetic radiation at moderate inductive hyperthermia in animals with sarcoma-45 initiated an increase in the tumor growth inhibition coefficient by 9 % (p < 0.05) and 27 % (p < 0.05) respectively, compared to the separate action of the drugs. Clinical studies were provided on 6 patients with bone sarcoma of a high degree of malignancy. Those patients were treated with neoadjuvant therapy which included the induction of doxorubicin and application of the local electromagnetic irradiation in conditions of moderate hyperthermia.
Product Description
popup.authors
Diedkov Anatolii H.
Dasiukevych Olha Yo.
Ostafiichuk Vasyl V.
Rykhalskyi Oleksandr Yu.
popup.nrat_date
2025-01-28
